All Stories

  1. The Overlooked Outcome: Decision Regret in the Surgical Management of Differentiated Thyroid Cancer
  2. Interobserver Agreement Among Thyroid Ultrasound Operators in Defining Thyroid Nodules as Subcapsular
  3. Designing a SPIKES-based protocol for communicating uncertainty in indeterminate thyroid cytology: a mixed-method analysis within a pilot study
  4. Long-Term Surveillance for Benign Thyroid Nodules
  5. Prospective Validation of ATA Risk Score for Papillary Thyroid Microcarcinoma: An ITCO Real-World Study
  6. Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study)
  7. Validation of ACR TI-RADS performance in transition age: results from a multicenter retrospective study by the TALENT study group
  8. Serum microRNA-146a-5p and microRNA-221-3p as potential clinical biomarkers for papillary thyroid carcinoma
  9. Effects of lenvatinib on glucose, cholesterol, triglycerides and estimated cardiovascular risk in patients with advanced thyroid cancer
  10. Data-driven Thyroglobulin Cutoffs for Low- and Intermediate-risk Thyroid Cancer Follow-up: ITCO Real-world Analysis
  11. Thyroid nodules: diagnosis and management
  12. The Pathologist Counts—So Many Variables in the Risk Stratification of Thyroid Cancers
  13. Ontology-Based Data Preparation in Healthcare: The Case of the AMD-STITCH Project
  14. Drawing as a Way of Knowing: How a Mapping Model Assists Preoperative Evaluation of Patients with Thyroid Carcinoma
  15. A Prospective Multicenter Study Examining the Relationship Between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis
  16. International Expert Consensus on US Lexicon for Thyroid Nodules
  17. Laterocervical lymph node metastases from suspected thyroidal primary site that turned out to be metastases of lung cancer: A case report
  18. The effects of multitarget kinase inhibitors on glucose, cholesterol, and triglyceride levels
  19. Ultrasound screening for thyroid nodules and cancer in individuals with family history of thyroid cancer: a micro-costing approach
  20. The role of miR-139-5p in radioiodine-resistant thyroid cancer
  21. A Reappraisal of Suspicious Sonographic Features of Thyroid Nodules: Shape Is Not an Independent Predictor of Malignancy
  22. Predicting recurrence of thyroid cancer: how to.
  23. Prevalence of Thyroid Nodules and Thyroid Cancer in Individuals with a First-Degree Family History of Non-Medullary Thyroid Cancer: A Cross-Sectional Study Based on Sonographic Screening
  24. Size Doesn't Matter! Is Active Surveillance Feasible for Low-Risk Thyroid Cancers up to 20 mm?
  25. What Is the Risk of Missed Malignancies in the Longterm Follow-up of Thyroid Nodules?
  26. Precision oncology for RET-related tumors
  27. New hope for patients with BRAF V600E-mutant anaplastic thyroid cancer: lights and shadows
  28. The legacy of the COVID-19 pandemics for thyroid cancer patients: towards the application of clinical practice recommendations
  29. Artificial Intelligence for Thyroid Nodule Characterization: Where Are We Standing?
  30. The COVID-19 outbreak and de-escalation of thyroid cancer diagnosis and treatment
  31. Is Lenvatinib Better Than Sorafenib as First-Line Treatment of Radioiodine Refractory Differentiated Thyroid Cancers?
  32. Establishment and maintenance of thyroid organoids from human cancer cells
  33. Diagnostic accuracy of ultrasonographic features in detecting thyroid cancer in the transition age: a meta-analysis
  34. Levothyroxine Treatment of Subclinical Hypothyroidism in the Elderly Does Not Improve Hemoglobin Levels
  35. Multimodal Feature Fusion and Knowledge-Driven Learning via Experts Consult for Thyroid Nodule Classification
  36. A Network-Based Analysis of Disease Modules From a Taxonomic Perspective
  37. US-Elastography With Different Techniques for Thyroid Nodule Characterization: Systematic Review and Meta-analysis
  38. 18F–FDG–PET/CT May Reduce Unnecessary Thyroid Surgery in Cytologically Indeterminate Thyroid Nodules
  39. Non-Marked Hypoechogenic Nodules: Multicenter Study on the Thyroid Malignancy Risk Stratification and Accuracy Based on TIRADS Systems Comparison
  40. Supporting Personalized Health Care With Social Media Analytics: An Application to Hypothyroidism
  41. Inappropriate Use of Thyroid Ultrasound Is Common in Clinical Practice
  42. Management of cytologically indeterminate thyroid nodules: <i>primum non nocere</i>
  43. Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4)
  44. Preoperative Ultrasonography in the Evaluation of Suspected Familial Non-Medullary Thyroid Cancer: Are We Able to Predict Multifocality and Extrathyroidal Extension?
  45. Integrating categorical and structural proximity in Disease Ontologies
  46. Thyroid Nodule Characterization: How to Assess the Malignancy Risk. Update of the Literature
  47. TIRADS, SRE and SWE in INDETERMINATE thyroid nodule characterization: Which has better diagnostic performance?
  48. Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients
  49. Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer
  50. Molecular analysis of fine-needle aspiration cytology in thyroid disease: where are we?
  51. Selective Use of Radioactive Iodine Therapy for Papillary Thyroid Cancers With Low or Lower-Intermediate Recurrence Risk
  52. The ultrasound risk stratification systems for thyroid nodule have been evaluated against papillary carcinoma. A meta-analysis
  53. Performance of EU-TIRADS in malignancy risk stratification of thyroid nodules: a meta-analysis
  54. Sonographic Risk Stratification Systems for Thyroid Nodules as Rule-Out Tests in Older Adults
  55. Artificial Intelligence: What Is It and How Can It Expand the Ultrasound Potential in the Future?
  56. Loss of Function SETD2 Mutations in Poorly Differentiated Metastases from Two Hürthle Cell Carcinomas of the Thyroid
  57. Cancer Care During COVID-19 Era: The Quality of Life of Patients With Thyroid Malignancies
  58. Analytical validation of a novel targeted next-generation sequencing assay for mutation detection in thyroid nodule aspirates and tissue
  59. Contemporary Thyroid Nodule Evaluation and Management
  60. Endocrine surgery during COVID-19 pandemic: do we need an update of indications in Italy?
  61. Risk of Kidney Dysfunction IN Nafld
  62. Fournier's gangrene during lenvatinib treatment: A case report
  63. Computer-aided diagnostic system for thyroid nodule sonographic evaluation outperforms the specificity of less experienced examiners
  64. Performance of a dual-component molecular assay in cytologically indeterminate thyroid nodules
  65. Diagnostic Performance of Neck Ultrasonography in the Preoperative Evaluation for Extrathyroidal Extension of Suspicious Thyroid Nodules
  66. Low-risk papillary thyroid microcarcinoma: Optimal management toward a more conservative approach
  67. Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma
  68. Nodular Thyroid Disease in the Era of Precision Medicine
  69. Performance of contrast-enhanced ultrasound (CEUS) in assessing thyroid nodules: a systematic review and meta-analysis using histological standard of reference
  70. Does the Site of Origin of the Microcarcinoma with Respect to the Thyroid Surface Matter? A Multicenter Pathologic and Clinical Study for Risk Stratification
  71. Can ultrasound systems for risk stratification of thyroid nodules identify follicular carcinoma?
  72. Taller-Than-Wide Shape: A New Definition Improves the Specificity of TIRADS Systems
  73. Clinically silent thyroid cancers: drop those needles and scalpels!
  74. Comment on: BRAF mutation analysis by ARMS‐PCR refines thyroid nodule management
  75. Screening for differentiated thyroid cancer in selected populations
  76. Thyroid hormone therapy in differentiated thyroid cancer
  77. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy
  78. SONOGRAPHICALLY ESTIMATED THYROID NODULE MALIGNANCY RISK: STRENGTHS AND LIMITATIONS IN CLINICAL PRACTICE
  79. Molecular defects in thyroid dysgenesis
  80. Prognosis of patients with differentiated thyroid carcinomas having a preoperative cytological report of indeterminate at low or high risk. A multicenter study
  81. Thyroid cancer patients with no evidence of disease: the need for repeat neck ultrasound
  82. Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments
  83. Prospective Evaluation of Semiquantitative Strain Ratio and Quantitative 2D Ultrasound Shear Wave Elastography (SWE) in Association with TIRADS Classification for Thyroid Nodule Characterization
  84. Indeterminate thyroid nodules ( TIR 3A/ TIR 3B) according to the new Italian Reporting System for Thyroid Cytology: a cytomorphological study
  85. Levothyroxine Treatment Increases Mortality in Patients with Heart Failure
  86. Is thyroid nodule location associated with malignancy risk?
  87. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
  88. A synonymous RET substitution enhances the oncogenic effect of an in-cis missense mutation by increasing constitutive splicing efficiency
  89. Reducing the number of unnecessary thyroid biopsies while improving diagnostic accuracy: towards the “right” TIRADS
  90. Thyroid nodule recurrence following lobo-isthmectomy: incidence, patient’s characteristics, and risk factors
  91. Sonographically Estimated Risks of Malignancy for Thyroid Nodules Computed with Five Standard Classification Systems: Changes over Time and Their Relation to Malignancy
  92. Follow-up of differentiated thyroid cancer – what should (and what should not) be done
  93. Sonographic presentation of metastases to the thyroid gland: a case-series
  94. The distinctive traits of Follicular thyroid cancer and Hürthle cell cancer
  95. Thyroid Dysfunction and Nonalcoholic Fatty Liver Disease: We Need New Larger and Well-Designed Longitudinal Studies
  96. Lack of association between obesity and aggressiveness of differentiated thyroid cancer
  97. The Diagnosis and management of thyroid nodules
  98. What's new on differentiated thyroid cancer?
  99. The level of agreement between different clinicians in the evaluation of thyroid nodules
  100. Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory
  101. 8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2)
  102. Temporal Changes in Thyroid Nodule Volume: Lack of Effect on Paranodular Thyroid Tissue Volume
  103. MicroRNA-based molecular classification of papillary thyroid carcinoma
  104. Identification of Thyroid-Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow-Up
  105. Ultrasonography scoring systems can rule out malignancy in cytologically indeterminate thyroid nodules
  106. Severe hypoglycemia in patients with known diabetes requiring emergency department care: A report from an Italian multicenter study
  107. Risk Stratification of Neck Lesions Detected Sonographically During the Follow-Up of Differentiated Thyroid Cancer
  108. Grey-Scale Analysis Improves the Ultrasonographic Evaluation of Thyroid Nodules
  109. Association of Thyroid Diseases with Primary Extra-Thyroidal Malignancies in Women: Results of a Cross-Sectional Study of 6,386 Patients
  110. Influence of Thyrotropin and Thyroid Volume on Basal Serum Calcitonin
  111. A comprehensive score to diagnose Hashimoto’s thyroiditis
  112. Thyroglobulin in Lymph Node Fine-Needle Aspiration Washout
  113. Thyroid autoimmunity and risk of malignancy in thyroid nodules submitted to fine‐needle aspiration cytology
  114. Thyroglobulin in fine-needle aspiration wash-out diagnostic performance: a meta-analysis
  115. Serum calcitonin, thyrotropin, and goiter
  116. Thyroid Function in Infertile Patients Undergoing Assisted Reproduction
  117. Intrinsic factors affecting adequacy of thyroid nodule fine‐needle aspiration cytology
  118. Interpretation of serum calcitonin in patients with chronic autoimmune thyroiditis
  119. Therapy of Hyperthyroidism in Pregnancy and Breastfeeding
  120. Medical Treatment of Hyperthyroidism: State of the Art
  121. Diagnostic Accuracy of rhTSH Test with Neck Ultrasonography in Differentiated Thyroid Cancer Follow-up
  122. Medullary Thyroid Carcinoma and Tuberous Sclerosis